UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000011770
Receipt number R000006675
Scientific Title Intraoperative photodynamic diagnosis of prostate cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA) to detect the residual cancer in the surgical margin of prostatectomy
Date of disclosure of the study information 2013/09/14
Last modified on 2019/08/09 09:44:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Intraoperative photodynamic diagnosis of prostate cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA) to detect the residual cancer in the surgical margin of prostatectomy

Acronym

Intraoperative photodynamic diagnosis of prostate cancer

Scientific Title

Intraoperative photodynamic diagnosis of prostate cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA) to detect the residual cancer in the surgical margin of prostatectomy

Scientific Title:Acronym

Intraoperative photodynamic diagnosis of prostate cancer

Region

Japan


Condition

Condition

Localized prostate cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the efficacy of the intraoperative photodynamic diagnosis of prostate cancer using fluorescence cystoscopy with 5-aminolevulinic acid (5-ALA) to detect the residual cancer in the surgical margin of prostatectomy

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Diagnostic accuracy: The levels in images of the 5-ALA-induced fluorescence were compared with the pathological results.

Key secondary outcomes

Safety: The occurrence frequency and degree of adverse event were investigated through the procedures.


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine Device,equipment Maneuver

Interventions/Control_1

Three to four hours prior to operation 1.0g 5-aminolevulinic acid (5-ALA) (unapproved drug by Japanese pharmaceutical affairs law) dissolved in 50ml of 5% glucose solution was administrated orally (1.0g/50ml).
For fluorescence excitation a blue light source (D-Light AF System) was used. Under fluorescence light guidance outputted by light source apparatus and videocamera system (Endovision TELECAM SL/IPM-PPD System), fluorescence lesions were recorded and resected.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male

Key inclusion criteria

Patient who has localized prostate cancer indicated for prostatectomy (open surgery, laparoscopic surgery or robot-assisted surgery)

Key exclusion criteria

Patient who has potential complication of local disorder and systematic absorption of 5-ALA such as solar photosensitivity nad liver dysfunction.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akio Matsubara

Organization

Hiroshima University

Division name

Department of Urology

Zip code


Address

1-2-3, kasumi, Minami-ku, Hiroshima, Hiroshima, Japan

TEL

082-257-5242

Email

urology@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Kanao Kobayashi

Organization

Hiroshima University

Division name

Department of Urology

Zip code


Address

1-2-3, kasumi, Minami-ku, Hiroshima, Hiroshima, Japan

TEL

082-257-5242

Homepage URL


Email

urology@hiroshima-u.ac.jp


Sponsor or person

Institute

Department of Urology, Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

広島大学病院


Other administrative information

Date of disclosure of the study information

2013 Year 09 Month 14 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 05 Month 02 Day

Date of IRB

2011 Year 06 Month 06 Day

Anticipated trial start date

2011 Year 06 Month 01 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 09 Month 14 Day

Last modified on

2019 Year 08 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006675


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name